The Stanford Study That Changed Everything

When Stanford Medicine published its study on ibogaine treatment for veterans with traumatic brain injuries in January 2024, the findings were so striking that they prompted immediate congressional attention.

The Study Design

The research team, led by Dr. Nolan Williams, followed 30 special operations veterans who had traveled to a clinic in Mexico for ibogaine treatment. All participants had significant histories of trauma exposure and were experiencing symptoms of PTSD, depression, and cognitive impairment.

The veterans underwent comprehensive neuropsychological testing before treatment, one month after, and at follow-up intervals. The results were remarkable by any standard.

The Findings

On average, participants reported a 88% reduction in PTSD symptoms. Depression scores dropped by 87%. Anxiety decreased by 81%. Cognitive function — including memory, attention, and executive function — improved significantly. Perhaps most striking: suicidal ideation, present in many participants before treatment, was virtually eliminated at the one-month follow-up.

These are not incremental improvements. These are the kinds of numbers that, in a conventional drug trial, would trigger immediate FDA fast-track designation.

Political Fallout

The study landed in Washington at a moment of acute awareness about the veteran suicide crisis. Former Texas Governor Rick Perry, himself a veteran advocate, appeared on the Joe Rogan Experience in January 2025 alongside ibogaine advocate Bryan Hubbard to discuss the findings. The episode was viewed by tens of millions of people.

Congressional hearings followed. The Veterans Affairs committee began examining pathways to make ibogaine accessible to veterans, potentially through clinical trials or compassionate use exemptions.

What Comes Next

The Stanford team is now conducting a larger, randomized controlled trial. The FDA has granted ibogaine Breakthrough Therapy designation for PTSD in veterans — a designation that accelerates the development and review process.

The scientific consensus is shifting. Ibogaine is no longer fringe medicine. It is, increasingly, the subject of serious institutional research and genuine policy consideration.